Volume 20, Number 3—March 2014
CME ACTIVITY - Research
Use of Drug-Susceptibility Testing for Management of Drug-Resistant Tuberculosis, Thailand, 2004–2008
|Turnaround variable||Median (IQR), d
|RIF-resistant TB (n = 18)||MDR TB (n = 112)||Total RIF-resistant and MDR TB|
|Time from sputum collection to clinic receipt of results||75.0 (49.0–112.0)||100.0 (67.3–137.5)||97.5 (66.0–133.3)|
|Time from clinic receipt of results to review by physician†||9.0 (0.8–16.5)||7.0 (1.0–21.8)||7.0 (1.0–21.0)|
|Time from sputum collection to result review by physician†||83.0 (53.0–130.3)||111.0 (77.3–153.3)||109.5 (73.0–150.0)|
*The 130 TB patients represented here were among 208 patients from 5 Thailand provinces participating in the Thailand Active TB Surveillance Network. Calculations were restricted to patients who had complete information for sputum collection date, date of receipt of DST at the clinic, and date of the first physician visit after availability of DST results. Three MDR TB patients were missing initial sputum collection date, 14 RIF-resistant and 41 MDR TB patients were missing date of receipt of DST results at the clinic, and 16 RIF-resistant and 47 MDR TB patients were missing date of first clinic visit following receipt of DST results. DST, drug susceptibility test; RIF, rifampin; MDR, multidrug-resistant; TB, tuberculosis; IQR, interquartile range.
†Represents first post-DST clinic visit.